GSK plc

GSK plc Goodwill/Assets

The Goodwill to Total Assets Ratio of GSK plc (GSK.L) as of Nov 12, 2026 is 11.48 %. In the previous year, Goodwill to Total Assets Ratio was 11.74 % — a change of -2.21% (lower).

Goodwill/Assets

11.48 %

YoY

-2.21%

Last updated:

Goodwill to Total Assets Ratio of GSK plc is 2025 11.48 % . Goodwill to Total Assets Ratio of GSK plc was 2024 11.74 % . It decreases by -2.21% lower compared to the previous year.

The GSK plc Goodwill/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill/Assets
Date
Goodwill/Assets
Jan 1, 2018
9.97 GBP
Jan 1, 2019
13.25 GBP
Jan 1, 2020
13.18 GBP
Jan 1, 2021
13.34 GBP
Jan 1, 2022
11.71 GBP
Jan 1, 2023
11.54 GBP
Jan 1, 2024
11.74 GBP
Jan 1, 2025
11.48 GBP
The GSK plc Goodwill/Assets history
YEARGoodwill/AssetsYoY
11.48 %-2.21%
11.74 %+1.72%
11.54 %-1.47%
11.71 %-12.18%
13.34 %+1.25%
13.18 %-0.59%
13.25 %+32.94%
9.97 %-1.97%
10.17 %+0.73%
10.10 %+4.53%
9.66 %+5.43%
9.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Goodwill to Total Assets Ratio of GSK plc is 11.48 % in 2025.

Goodwill to Total Assets Ratio of GSK plc changed from 11.74 % to 11.48 %, representing a -2.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill to Total Assets Ratio GSK plc since 2006 – with annual values, charts, and detailed analysis.

The Goodwill/Assets ratio shows what percentage of total assets consists of acquisition goodwill. High ratios may indicate impairment risk.

Goodwill to Total Assets Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill to Total Assets Ratio's GSK plc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GSK plc

All Key Metrics — GSK plc